# Clinical Trials Data KRAS - Document 6

# NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT00856375

"eligibilityCriteria": "Inclusion Criteria:\n\n\* metastatic colorectal cancer\n\* tumor with k-ras mutation\n\nExclusion Criteria:\n\n\* More than 1 prior regimen for treatment of metastatic disease",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, a patient with a KRAS gene mutation would indeed be eligible. The inclusion criteria specify that the patient must have metastatic colorectal cancer with a KRAS mutation. As long as the patient also meets other criteria (such as having not received more than one prior regimen for treating metastatic disease), they would be eligible to participate in this trial.